---
schema_version: "secwatch.filing_event.v1"
accession: "0001651944-24-000044"
form_type: "8-K"
ticker: null
cik: "0001651944"
company_name: "DermTech, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:56:36.128158+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# DermTech Q1 revenue up 11% to $3.8M; net loss narrows to $20M

## Summary
- Test revenue $3.7M (+7% YoY); billable sample volume ~15,360 (-14% YoY).
- Net loss $20.0M ($0.58/share) vs. $31.3M ($1.02/share) in Q1 2023.
- Test gross margin improved to 16% from -11% YoY on 19% lower cost of test revenue.
- Sales & marketing expenses down 49% to $7.8M; G&A down 15% to $10.1M.
- Cash, equivalents and marketable securities $42.4M at March 31, 2024.

## SEC filing metadata
- accession: 0001651944-24-000044
- form_type: 8-K
- cik: 0001651944
- company_name: DermTech, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651944/000165194424000044/0001651944-24-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651944/000165194424000044/dmtk-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651944-24-000044
- JSON: https://secwatch.observer/filing/0001651944-24-000044.json
- Plain text: https://secwatch.observer/filing/0001651944-24-000044.txt

## Key facts
- Earnings Releases
  DermTech, Inc. reported the quarter ended March 31, 2024 results: revenue $3.8 million, net income Net loss was $20.0 million, EPS ($0.58) per share.
  - Period: the quarter ended March 31, 2024
  - Revenue: $3.8 million
  - Net income: Net loss was $20.0 million
  - EPS: ($0.58) per share
  - Result: reported results
  source text: First-Quarter 2024 Financial Results • Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. • Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. • Total revenue was $3.8 million, an 11 percent increase from the first quarter of 2023, driven by higher test revenue. • Cost of test revenue was $3.1 million, a 19 percent decrease from the first quarter of 2023, yielding a test gross margin of 16 percent, compared to negative 11 percent for the first quarter of 2023. Cost of test revenue decreased primarily because of lower employee-related costs. • Sales and marketing expenses were $7.8 million, a 49 percent decrease from the first quarter of 2023. The decrease was primarily attributable to lower employee-related and marketing expenditures. • Research and development expenses were $3.3 million, a 26 percent decrease from the first quarter of 2023, largely due to lower employee-
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651944/000165194424000044/0001651944-24-000044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.